Selecting Therapy for AML Without Predictive Biomarkers or Therapeutically Actionable Genomic or Molecular Alterations

Expert faculty answer audience questions from a live satellite symposium presented at ASCO 2022 on the management of MDS, from Clinical Care Options (CCO)

Rami S. Komrokji, MD
Program Director Amy E. DeZern, MD, MHS Amer Zeidan, MBBS, MPH Released: August 9, 2022

Commentary on the evolving therapeutic landscape in peripheral T-cell lymphomas with a focus on EZH1/2 inhibition, from Clinical Care Options (CCO)

Steven M. Horwitz, MD
Program Director Pamela B. Allen, MD Pierluigi Porcu, MD Released: August 8, 2022

Video featuring Jesús Berdeja, MD, and Sagar Lonial, MD, discussing the latest evidence on approved and investigational CAR T-cell therapies for multiple myeloma, from Clinical Care Options (CCO)

Jesús G. Berdeja, MD Sagar Lonial, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 5, 2022 Expired: August 4, 2023

Expert webcast recording of live webinar on selecting therapy and managing toxicities for indolent B-cell lymphomas, from Clinical Care Options (CCO)

Elizabeth Brém, MD
Program Director Christopher R. Flowers, MD, MS
Program Director Pallawi Torka, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: August 3, 2022 Expired: August 2, 2023